Conditions: HIV
Keywords: HIV Lymphoid fibrosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 31
Healthy volunteers: no

Brief summary:
The investigators propose a proof-of-concept, pathogenesis-oriented, randomized, placebo-controlled pilot study to assess whether the addition of an angiotensin converting enzyme (ACE) inhibitor to standard Highly Active Antiretroviral Therapy (HAART) reverses lymphoid fibrosis, and whether this leads to more effective HIV-specific host immune responses and an accelerated clearance of the latent reservoir.

Detailed description:

Arms:
arm 1: Active group arm 2: Placebo group

Interventions: intervention 1: Lisinopril intervention 2: Placebo
Intervention descriptions: intervention 1: Lisinopril 20mg QD x 24 weeks intervention 2: Placebo QD x24wks

Protocol document: